P16 overexpression in BRAF-mutated gastrointestinal stromal tumors

References

• Doyle LA, Hornick JL. Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase. Histopathology. 2014;64(1):53–67.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83.
   PubMed Web of Science ®Google Scholar
• Rossi S, Gasparotto D, Miceli R, et al. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study. Am J Surg Pathol. 2015;39(7):922–930.
   PubMed Web of Science ®Google Scholar
• Nannini M, Biasco G, Astolfi A, et al. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). J Med Genet. 2013;50(10):653–661.
   PubMed Web of Science ®Google Scholar
• Cui Y, Guadagno TM. B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells. Oncogene. 2008;27(22):3122–3133.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954.
   PubMed Web of Science ®Google Scholar
• Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008;47(10):853–859.
   PubMed Web of Science ®Google Scholar
• Hostein I, Faur N, Primois C, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010;133(1):141–148.
   PubMed Web of Science ®Google Scholar
• Miranda C, Nucifora M, Molinari F, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2012;18(6):1769–1776.
   PubMed Web of Science ®Google Scholar
• Agaimy A, Terracciano LM, Dirnhofer S, et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol. 2009;62(7):613–616.
   PubMed Web of Science ®Google Scholar
• Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res. 1997;237(1):7–13.
   PubMed Web of Science ®Google Scholar
• Ayhan S, Isisag A, Saruc M, et al. The role of pRB, p16 and cyclin D1 in colonic carcinogenesis. Hepatogastroenterology. 2010;57(98):251–256.
   PubMed Web of Science ®Google Scholar
• Angiero F, Berenzi A, Benetti A, et al. Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res. 2008;28(5A):2535–2539.
   PubMed Web of Science ®Google Scholar
• Buajeeb W, Poomsawat S, Punyasingh J, et al. Expression of p16 in oral cancer and premalignant lesions. J Oral Pathol Med. 2009;38(1):104–108.
   PubMed Web of Science ®Google Scholar
• Jung SH, Suh KS, Kang DY, et al. Expression of DOG1, PDGFRA, and p16 in Gastrointestinal Stromal Tumors. Gut Liver. 2011;5(2):171–180.
   PubMed Web of Science ®Google Scholar
• Steigen SE, Bjerkehagen B, Haugland HK, et al. Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Mod Pathol. 2008;21(1):46–53.
   PubMed Web of Science ®Google Scholar
• Schmieder M, Wolf S, Danner B, et al. p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome. Neoplasia. 2008;10(10):1154–1162.
   PubMed Web of Science ®Google Scholar
• Haller F, Agaimy A, Cameron S, et al. Expression of p16INK4A in gastrointestinal stromal tumours (GISTs): two different forms exist that independently correlate with poor prognosis. Histopathology. 2010;56(3):305–318.
   PubMed Web of Science ®Google Scholar
• Gill AJ, Chou A, Vilain RE, et al. “Pediatric-type” gastrointestinal stromal tumors are SDHB negative (“type 2”) GISTs. Am J Surg Pathol. 2011;35(8):1245–1247. author reply 1247-8.
   PubMed Web of Science ®Google Scholar
• Rege TA, Wagner AJ, Corless CL, et al. “Pediatric-type” gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior. Am J Surg Pathol. 2011;35(4):495–504.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Killian JK, Wang Z-F, et al. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol. 2013;37(2):234–240.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Remillard SP, Zhang Y-X, et al. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol. 2013;26(2):289–294.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–873.
   PubMed Web of Science ®Google Scholar
• Zheng S, Huang K-E, Pan Y-L, et al. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance. Gastric Cancer. 2015;18(4):796–802.
   PubMed Web of Science ®Google Scholar
• Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369(9574):1731–1741.
   PubMed Web of Science ®Google Scholar
• Daniels M, Lurkin I, Pauli R, et al. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett. 2011;312(1):43–54.
   PubMed Web of Science ®Google Scholar
• Huss S, Künstlinger H, Wardelmann E, et al. A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del). Mod Pathol. 2013;26(7):1004–1012.
   PubMed Web of Science ®Google Scholar
• Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53(3):245–266.
   PubMed Web of Science ®Google Scholar
• Rossi S, Sbaraglia M, Dell’Orto MC, et al. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors. Oncotarget. 2016;7(21):30109–30118.
   PubMed Web of Science ®Google Scholar
• Falchook GS, Trent JC, Heinrich MC, et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 2013;4(2):310–315.
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95(5):581–586.
   PubMed Web of Science ®Google Scholar
• Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004;10((18 Pt 2):6388S–92S.
   PubMed Web of Science ®Google Scholar
• Houben R, Vetter-Kauczok CS, Ortmann S, et al. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol. 2008;128(8):2003–2012.
   PubMed Web of Science ®Google Scholar
• Wan PTC, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–867.
   PubMed Web of Science ®Google Scholar
• Schaefer I-M, Ströbel P, Cameron S, et al. Rhabdoid morphology in gastrointestinal stromal tumours (GISTs) is associated with PDGFRA mutations but does not imply aggressive behaviour. Histopathology. 2014;64(3):421–430.
   PubMed Web of Science ®Google Scholar
• Kim J, Jonasch E, Alexander A, et al. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res. 2009;15(1):81–90.
   PubMed Web of Science ®Google Scholar
• Lin Y-C, Diccianni MB, Kim Y, et al. Human p16gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression. Oncogene. 2007;26(49):7017–7027.
   PubMed Web of Science ®Google Scholar
• Dai CY, Furth EE, Mick R, et al. p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology. 2000;119(4):929–942.
   PubMed Web of Science ®Google Scholar
• Di Vinci A, Perdelli L, Banelli B, et al. p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer. 2005;114(3):414–421.
   PubMed Web of Science ®Google Scholar
• Romagosa C, Simonetti S, López-Vicente L, et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene. 2011;30(18):2087–2097.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130(10):1466–1478.
   PubMed Web of Science ®Google Scholar
• Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 2002;1602(1):73–87.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Rosen DG, Yao JL, et al. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Mod Pathol. 2006;19(10):1339–1343.
   PubMed Web of Science ®Google Scholar
• Michaloglou C, Vredeveld LCW, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436(7051):720–724.
   PubMed Web of Science ®Google Scholar
• Jacob K, Quang-Khuong D-A, Jones DTW, et al. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin Cancer Res. 2011;17(14):4650–4660.
   PubMed Web of Science ®Google Scholar
• Raabe EH, Lim KS, Kim JM, et al. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res. 2011;17(11):3590–3599.
   PubMed Web of Science ®Google Scholar
• Simonetti S, Serrano C, Hernández-Losa J, et al. Schwannomas, benign tumors with a senescent phenotype. Histol Histopathol. 2014;29(6):721–730.
   PubMed Web of Science ®Google Scholar
• Rodrigues LN, Correa GB, Diniz MG, et al. BRAF V600E and loss of heterozygosity assessment in benign oralneural tumours. J Oral Pathol Med. 2015;44(8):634–637.
   PubMed Web of Science ®Google Scholar
• Costa AM, Herrero A, Fresno MF, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2008;68(4):618–634.
   PubMed Web of Science ®Google Scholar
• Tornillo L, Duchini G, Carafa V, et al. Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest. 2005;85(7):921–931.
   PubMed Web of Science ®Google Scholar